Atritech
Plymouth
About Atritech
Atritech is a private company located in Minneapolis, Minnesota. The company was founded in 2000 and has developed proprietary technology focused on replacing long term anticoagulation therapy for patients with non-valvular atrial fibrillation at risk of stroke. The first implants of the WATCHMAN® Left Atrial Appendage Closure Technology were performed in Germany in August of 2002 and in the United States in October of 2003. Since then the company has conducted a large randomized clinical trial comparing the WATCHMAN® Left Atrial Appendage Closure Technology to long term Warfarin therapy in patients with non-valvular atrial fibrillation at risk of stroke. The WATCHMAN® Device is CE Marked and available in many markets outside the United States. The WATCHMAN® Device is currently available For Investigational Use Only in the United States.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 10,001+
- Total funding: $83.6M
- Funding stage: M&A
- Last round: Series Unknown (Mar 2009)
- Website: atritech.net
- Phone: 763.258.0250
Industries & Categories
Clinical Trials, Health Care, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/atritech-264295 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.